With his international management experience and extensive network in various life science markets, Thomas Bachmann is a great asset to Cytosurge and will continue to develop its strategic future markets.
Zurich | August 25, 2020
We are pleased to announce Thomas Bachmann as a new member of our Board of Directors. Thanks to his proven and long-standing strategic management experience and his extensive network in the biotechnology and laboratory equipment industry, Mr. Thomas Bachmann brings valuable industry know-how and thus contributes to the further professionalization of Cytosurge's strategic supervisory board. Thomas Bachmann complements the company's Board of Directors alongside the existing founding members, Dr. Pascal Behr, CEO, and Dr. Michael Gabi, Master Inventor.
Cytosurge was founded in 2009 as an ETH spin-off and has experienced steady and rapid growth since the launch of its first commercial product, an add-on for atomic force microscopes. To ensure the sustainable development of the company in the future, the Board of Directors is currently being expanded to include experienced executives. With the election of Mr. Thomas Bachmann, the Board has now been successfully expanded with a well-known personality and brought to a level that further strengthens the company's strong international orientation and ambitions.
"With his impressive track record, Thomas Bachmann is a great asset to our company, and we are proud to have him as a new member of our Board of Directors," says Dr. Pascal Behr, CEO and founding member of Cytosurge. "With Mr. Bachmann, we have been able to attract a proven leader in the instrument and laboratory equipment industry. He has more than 30 years of experience in the management, strategy and development of international and listed companies in complex business areas and thus brings valuable experience to our company".
From 2005 to 2012, Thomas Bachmann was the successful CEO of Tecan, a leading Swiss company in the laboratory equipment industry for many years. He was also President of Bruker BioSpin, a leading global manufacturer of analytical and preclinical magnetic resonance equipment, from 2013 to 2015. Until the end of 2019, Thomas Bachmann also served for almost seven years as CEO and a member of the Supervisory Board of Eppendorf, one of the world's best-known and most successful suppliers of laboratory equipment in the Life Science sector. Under his leadership, Eppendorf was able to increase and improve its sales and market positioning in a very impressive manner.
Cytosurge intends to further strengthen and expand its position as a provider of disruptive solutions in the field of single cell biology in the future. In particular, the rapidly growing markets for genetic editing and for the generation of genetically modified cell lines in biotechnology offer exciting new sales opportunities. With the appointment of Thomas Bachmann as a member of the Board of Directors, a further important step has now been taken to strengthen the company's position ahead of this venture and to sustainably advance in these strategic future markets.
We are very pleased to welcome Mr. Bachmann on board and look forward to a productive collaboration.
firstname.lastname@example.org, +41 43 544 87 20
Thomas Bachmann is a new board member of Cytosurge.
Board of Directors of Cytosurge - from left Dr. Pascal Behr, Dr. Michael Gabi, Thomas Bachmann.
Cytosurge AG develops, manufactures and distributes state-of-the-art nanotechnology solutions and systems based on its patented FluidFM® technology. At the heart of the technology are the hollow FluidFM probes, which have apertures down to 300 nm, enabling the handling of femtoliter volumes.
Cytosurge brings with its FluidFM solutions significant benefits to a wide range of applications in life sciences, biophysics and mechanobiology. Unique benefits include quantitative volume measurements of injected compounds into single cells during drug development, improved CRISPR gene editing by direct delivery into the nucleus, isolation of selected cells directly from confluent culture, 2.5D nano-printing down to submicron levels, or single cell adhesion and colloidal probe measurements.
For more information, visit